etx2514
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02971423)
Timeline
Indications
Mechanism of action
- ADC-11INHIBITOR
ampC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- etx2514
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04018950 | Phase 1 | Jun 21, 2019 | Entasis Therapeutics |
| NCT03985410 | Phase 1 | May 23, 2019 | Entasis Therapeutics |
| NCT03894046 | Phase 3 | Apr 3, 2019 | Entasis Therapeutics |
| NCT03303924 | Phase 1 | Aug 21, 2017 | Clinartis, Entasis Therapeutics |
| NCT02971423 | Phase 1 | Oct 1, 2016 | Entasis Therapeutics, Nucleus Network Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Entasis Therapeutics | For profit | 5 | 5 | 2 | 2016 |
| Clinartis | For profit | 1 | 0 | 1 | 2017 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1